“With submission in Canada and the UK, ARS Pharma now has approval or has filed for approval in jurisdictions comprising more ...

Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy ...

“The inclusion of neffy on Express Scripts’ Commercial National Formularies significantly improves access to life-saving allergy treatment,” said Sal Grausso, Head of Market Access at ARS Pharma.

Among the numerous clinical trials conducted by ARS Pharma and our licensing partners in support of filings in Japan and China, the Company also conducted a Phase 3 study in Japanese pediatric ...

Among the numerous clinical trials conducted by ARS Pharma and our licensing partners in support of filings in Japan and China, the Company also conducted a Phase 3 study in Japanese pediatric ...

ARS Pharma retains all U.S. rights for neffy and has existing licensing partnerships in China, Japan, Australia and New Zealand with Pediatrix Therapeutics, Alfresa Pharma, and CSL Seqirus ...

This expanded access aligns with ARS Pharma’s commitment to reducing barriers to care and improving outcomes for patients who rely on epinephrine during allergy emergencies. ARS Pharma ...

Among the numerous clinical trials conducted by ARS Pharma and our licensing partners in support of filings in Japan and China, the Company also conducted a Phase 3 study in Japanese pediatric ...